Title:
COMPOUND FOR INHIBITING TANKYRASE, AND MEDICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/090728
Kind Code:
A1
Abstract:
The present invention relates to a compound for inhibiting tankyrase, and medical use thereof. Since the compound according to the present invention inhibits the activity of enzyme tankyrase (TNKS), inhibits target β-catenin gene expression and active β-catenin protein expression, stabilizes the AXIN2 protein level, and exhibits anti-cancer activity in human colon cancer cell lines, the compound can be used as an anti-cancer agent. In addition, when coadministered with a conventional anti-cancer agent 7-ethyl-10-hydroxycamptothecin (SN-38) or fluorouracil (5-FU), the compound exhibits synergistic effects in anti-cancer activity, and thus can be used in a combination therapy with a conventional anti-cancer agent.
Inventors:
AHN JI-YEON (KR)
RYU HWANI (KR)
SEO HYE-RAN (KR)
KIM HYO JEONG (KR)
KIM JAE-SUNG (KR)
SONG JIE YOUNG (KR)
HWANG SANG GU (KR)
KIM YOUNG HOON (KR)
BAE SU YEAL (KR)
CHOI NA YOUNG (KR)
KIM BO KYOUNG (KR)
RYU HWANI (KR)
SEO HYE-RAN (KR)
KIM HYO JEONG (KR)
KIM JAE-SUNG (KR)
SONG JIE YOUNG (KR)
HWANG SANG GU (KR)
KIM YOUNG HOON (KR)
BAE SU YEAL (KR)
CHOI NA YOUNG (KR)
KIM BO KYOUNG (KR)
Application Number:
PCT/KR2022/017305
Publication Date:
May 25, 2023
Filing Date:
November 07, 2022
Export Citation:
Assignee:
KOREA INST RADIOLOGICAL & MEDICAL SCIENCES (KR)
International Classes:
A61K31/502; A61K45/06; A61P35/00
Domestic Patent References:
| WO2013002879A1 | 2013-01-03 |
Foreign References:
| KR101924801B1 | 2018-12-04 | |||
| US20090163545A1 | 2009-06-25 | |||
| KR20150016406A | 2015-02-11 | |||
| KR20160063395A | 2016-06-03 |
Attorney, Agent or Firm:
TAEBAEK INTELLECTUAL PROPERTY LAW FIRM (KR)
Download PDF: